221 related articles for article (PubMed ID: 29119354)
1. Characteristics and outcomes of breast cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase I clinical trials.
Lynce F; Blackburn MJ; Cai L; Wang H; Rubinstein L; Harris P; Isaacs C; Pohlmann PR
Breast Cancer Res Treat; 2018 Feb; 168(1):35-41. PubMed ID: 29119354
[TBL] [Abstract][Full Text] [Related]
2. Analysis of lung cancer patients enrolled in CTEP (cancer therapy evaluation program)-sponsored phase I trials.
Gadgeel SM; Ivy P; Chen W; Mauer J; Smith D; Lorusso P
Clin Lung Cancer; 2011 Jul; 12(4):218-23. PubMed ID: 21726820
[TBL] [Abstract][Full Text] [Related]
3. Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials.
Chihara D; Lin R; Flowers CR; Finnigan SR; Cordes LM; Fukuda Y; Huang EP; Rubinstein LV; Nastoupil LJ; Ivy SP; Doroshow JH; Takebe N
Lancet; 2022 Aug; 400(10351):512-521. PubMed ID: 35964611
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of toxicities related to novel therapy in clinical trials for women with gynecologic cancer.
Lee YC; Wang L; Kohn EC; Rubinstein L; Ivy SP; Harris PJ; Lheureux S
Cancer; 2020 May; 126(10):2139-2145. PubMed ID: 32097505
[TBL] [Abstract][Full Text] [Related]
5. Consideration of older patients for enrollment in phase 1 clinical trials: Exploring treatment related toxicities and outcomes.
Buechel M; McGinnis A; Vesely SK; Wade KS; Moore KN; Gunderson CC
Gynecol Oncol; 2018 Apr; 149(1):28-32. PubMed ID: 29605046
[TBL] [Abstract][Full Text] [Related]
6. Analysis of esophagogastric cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase 1 trials.
Bando H; Rubinstein L; Harris P; Yoshino T; Doi T; Ohtsu A; Welch J; Takebe N
Gastric Cancer; 2017 May; 20(3):481-488. PubMed ID: 27510411
[TBL] [Abstract][Full Text] [Related]
7. Effect of Renal Dysfunction on Toxicity in Three Decades of Cancer Therapy Evaluation Program-Sponsored Single-Agent Phase I Studies.
Beumer JH; Ding F; Tawbi H; Lin Y; Viluh D; Chatterjee I; Rinker M; Chow SL; Ivy SP
J Clin Oncol; 2016 Jan; 34(2):110-6. PubMed ID: 26392101
[TBL] [Abstract][Full Text] [Related]
8. Phase I Clinical Trials in Acute Myeloid Leukemia: 23-Year Experience From Cancer Therapy Evaluation Program of the National Cancer Institute.
Zeidner JF; Karp JE; Blackford AL; Foster MC; Dees EC; Smith G; Ivy SP; Harris P
J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26553781
[TBL] [Abstract][Full Text] [Related]
9. Comparison of toxicity experienced by older versus younger patients enrolled in breast cancer clinical trials.
Mariano C; Francl M; Pope J; Wong L; Lim HJ; Lohrisch C
Clin Breast Cancer; 2015 Feb; 15(1):73-9. PubMed ID: 25445420
[TBL] [Abstract][Full Text] [Related]
10. Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program.
Drilon A; Eaton AA; Schindler K; Gounder MM; Spriggs DR; Harris P; Ivy SP; Iasonos A; Lacouture ME; Hyman DM
Cancer; 2016 Apr; 122(8):1228-37. PubMed ID: 26916138
[TBL] [Abstract][Full Text] [Related]
11. Similar efficacy for phase I trials in comparison with DTIC for advanced malignant melanoma: an analysis of melanoma outcomes in CTEP-sponsored phase I trials 1995-2011.
Luke JJ; Rubinstein LV; Smith GL; Ivy SP; Harris PJ
Melanoma Res; 2013 Apr; 23(2):152-8. PubMed ID: 23411478
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the Safety and Benefit of Phase I Oncology Trials for Patients With Primary CNS Tumors.
Gounder MM; Nayak L; Sahebjam S; Muzikansky A; Sanchez AJ; Desideri S; Ye X; Ivy SP; Nabors LB; Prados M; Grossman S; DeAngelis LM; Wen PY
J Clin Oncol; 2015 Oct; 33(28):3186-92. PubMed ID: 26282642
[TBL] [Abstract][Full Text] [Related]
13. Effect of Age on Clinical Outcomes in Phase 1 Trial Participants.
Mahipal A; Denson AC; Djulbegovic B; Lush R; Kumar A; Juan TH; Schell MJ; Sullivan DM
Cancer Control; 2015 Apr; 22(2):235-41. PubMed ID: 26068771
[TBL] [Abstract][Full Text] [Related]
14. Cumulative Toxicity in Targeted Therapies: What to Expect at the Recommended Phase II Dose.
Altzerinakou MA; Collette L; Paoletti X
J Natl Cancer Inst; 2019 Nov; 111(11):1179-1185. PubMed ID: 30838405
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of patients ≥65 years old with advanced cancer treated on phase I trials at MD ANDERSON CANCER CENTER.
Subbiah IM; Wheler JJ; Hess KR; Hong DS; Naing A; Fu S; Kurzrock R; Tsimberidou AM
Int J Cancer; 2017 Jan; 140(1):208-215. PubMed ID: 27599876
[TBL] [Abstract][Full Text] [Related]
16. Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated Toxicities.
Eaton A; Iasonos A; Gounder MM; Pamer EG; Drilon A; Vulih D; Smith GL; Ivy SP; Spriggs DR; Hyman DM
Clin Cancer Res; 2016 Feb; 22(3):553-9. PubMed ID: 26324741
[TBL] [Abstract][Full Text] [Related]
17. Patterns of National Cancer Institute-Sponsored Clinical Trial Enrollment in Black Adolescents and Young Adults.
Roth M; Beauchemin M; Kahn JM; Bleyer A
Cancer Med; 2021 Nov; 10(21):7620-7628. PubMed ID: 34592782
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of different recall periods for the US National Cancer Institute's PRO-CTCAE.
Mendoza TR; Dueck AC; Bennett AV; Mitchell SA; Reeve BB; Atkinson TM; Li Y; Castro KM; Denicoff A; Rogak LJ; Piekarz RL; Cleeland CS; Sloan JA; Schrag D; Basch E
Clin Trials; 2017 Jun; 14(3):255-263. PubMed ID: 28545337
[TBL] [Abstract][Full Text] [Related]
19. Recommendations for research priorities in breast cancer by the Coalition of Cancer Cooperative Groups Scientific Leadership Council: systemic therapy and therapeutic individualization.
Sparano JA; Hortobagyi GN; Gralow JR; Perez EA; Comis RL
Breast Cancer Res Treat; 2010 Feb; 119(3):511-27. PubMed ID: 19526354
[TBL] [Abstract][Full Text] [Related]
20. Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials.
Roberts TG; Goulart BH; Squitieri L; Stallings SC; Halpern EF; Chabner BA; Gazelle GS; Finkelstein SN; Clark JW
JAMA; 2004 Nov; 292(17):2130-40. PubMed ID: 15523074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
